Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
esomeprazole + sodium bicarbonate (Addpharma, Inc.)
- Development stage
- Unknown
- Lead developer
- Addpharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AD-207 (marketed as Esopid) is a fixed-dose combination drug developed by Addpharma, consisting of the proton pump inhibitor (PPI) esomeprazole and the antacid sodium bicarbonate. Classified as an "incrementally modified drug" (IMD) in South Korea, it is indicated for the treatment of gastrointestinal conditions such as erosive esophagitis and gastroesophageal reflux disease (GERD). The formulation utilizes sodium bicarbonate to neutralize gastric acid, which serves a dual purpose: it protects the acid-labile esomeprazole from degradation in the stomach and triggers the rapid activation of proton pumps, leading to a faster onset of acid suppression compared to conventional delayed-release PPI formulations. This immediate-release profile also allows for more flexible dosing relative to food intake. The drug was licensed to Yuhan Corporation for commercialization in the South Korean market.
- Brand names
- Esopid
- Other names
- Esomeprazole magnesium trihydrate + Sodium bicarbonate
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on esomeprazole + sodium bicarbonate (Addpharma, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on esomeprazole + sodium bicarbonate (Addpharma, Inc.).